Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Rating of “Moderate Buy” from Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $44.2857.

Several equities research analysts recently weighed in on ZBIO shares. Weiss Ratings downgraded shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Wall Street Zen raised Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Morgan Stanley boosted their price target on Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Finally, Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd.

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $31.42 on Wednesday. Zenas BioPharma has a one year low of $13.50 and a one year high of $44.60. The company’s 50-day moving average is $24.80 and its 200 day moving average is $22.77. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -3.71 and a beta of -1.03. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same quarter in the previous year, the firm earned ($0.80) earnings per share. Sell-side analysts expect that Zenas BioPharma will post -4.47 EPS for the current fiscal year.

Insider Buying and Selling

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was acquired at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the transaction, the chief executive officer owned 96,928 shares in the company, valued at $1,636,144.64. This represents a 162.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 22.00% of the company’s stock.

Institutional Trading of Zenas BioPharma

A number of large investors have recently made changes to their positions in the stock. Quarry LP raised its holdings in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Zenas BioPharma in the third quarter worth approximately $30,000. GF Fund Management CO. LTD. purchased a new stake in Zenas BioPharma in the fourth quarter worth approximately $38,000. BNP Paribas Financial Markets grew its position in Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares during the period. Finally, CWM LLC grew its position in Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after purchasing an additional 709 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.